Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
04 nov. 2024 07h00 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and...
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
25 oct. 2024 08h30 HE
|
Journey Medical Corporation
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy...
Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
12 août 2024 16h01 HE
|
Journey Medical Corporation
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase...
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
18 mars 2024 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily...
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
11 mars 2024 08h30 HE
|
Journey Medical Corporation
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that DFD-29 can be safely used for up to 16 weeks with...
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
05 janv. 2024 08h30 HE
|
Journey Medical Corporation
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea NDA submission supported by positive Phase...
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
06 déc. 2023 08h00 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses...
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
07 nov. 2023 16h01 HE
|
Journey Medical Corporation
Company generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023 GAAP net income increased to $16.8 million, or...
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)
20 oct. 2023 08h30 HE
|
Journey Medical Corporation
Study demonstrated systemic exposure of DFD-29 was significantly lower than that of Solodyn (105 mg) Data presented at 43rd Annual Fall Clinical Dermatology Conference New Drug Application...
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
08 août 2023 16h01 HE
|
Journey Medical Corporation
The Company generated total net revenues of $17.2 million in the second quarter of 2023, a 41% increase from $12.2 million in the first quarter of 2023 Announced positive topline results from two...